David Mathes
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 40 | 2025 | 119 | 10.210 |
Why?
| | Perforator Flap | 14 | 2025 | 34 | 5.300 |
Why?
| | Vascularized Composite Allotransplantation | 5 | 2024 | 31 | 3.140 |
Why?
| | Surgery, Plastic | 10 | 2025 | 50 | 3.080 |
Why?
| | Surgical Flaps | 12 | 2024 | 144 | 3.050 |
Why?
| | Transplantation Tolerance | 9 | 2024 | 37 | 2.600 |
Why?
| | Graft Survival | 16 | 2024 | 502 | 2.360 |
Why?
| | Graft Rejection | 14 | 2024 | 545 | 2.210 |
Why?
| | Epigastric Arteries | 15 | 2025 | 29 | 2.120 |
Why?
| | Rectus Abdominis | 5 | 2024 | 17 | 1.850 |
Why?
| | Skin Transplantation | 9 | 2018 | 84 | 1.700 |
Why?
| | Free Tissue Flaps | 5 | 2024 | 50 | 1.650 |
Why?
| | Microsurgery | 10 | 2024 | 77 | 1.600 |
Why?
| | Breast Neoplasms | 18 | 2025 | 2246 | 1.530 |
Why?
| | Myocutaneous Flap | 3 | 2024 | 10 | 1.510 |
Why?
| | Postoperative Complications | 21 | 2025 | 2831 | 1.500 |
Why?
| | Composite Tissue Allografts | 4 | 2016 | 8 | 1.490 |
Why?
| | Facial Transplantation | 5 | 2014 | 10 | 1.480 |
Why?
| | Breast Implants | 5 | 2024 | 20 | 1.380 |
Why?
| | Hand Transplantation | 5 | 2011 | 9 | 1.330 |
Why?
| | Surgical Wound Dehiscence | 4 | 2024 | 22 | 1.140 |
Why?
| | Immune Tolerance | 8 | 2024 | 373 | 1.120 |
Why?
| | Breast Implantation | 4 | 2024 | 13 | 1.120 |
Why?
| | Transplantation Chimera | 6 | 2014 | 57 | 1.080 |
Why?
| | Bone Marrow Transplantation | 6 | 2014 | 292 | 1.050 |
Why?
| | Acellular Dermis | 3 | 2022 | 11 | 0.990 |
Why?
| | Transplantation, Homologous | 14 | 2016 | 411 | 0.980 |
Why?
| | Fat Necrosis | 2 | 2022 | 10 | 0.900 |
Why?
| | Angiography | 5 | 2022 | 207 | 0.880 |
Why?
| | Iliac Artery | 1 | 2024 | 57 | 0.850 |
Why?
| | Abdominal Wall | 3 | 2025 | 26 | 0.840 |
Why?
| | Breast | 5 | 2024 | 155 | 0.830 |
Why?
| | Immunosuppressive Agents | 8 | 2024 | 855 | 0.830 |
Why?
| | Body Dysmorphic Disorders | 1 | 2023 | 11 | 0.820 |
Why?
| | Rhinoplasty | 1 | 2023 | 31 | 0.790 |
Why?
| | Retrospective Studies | 38 | 2025 | 16447 | 0.780 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 321 | 0.780 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.770 |
Why?
| | Preoperative Care | 5 | 2012 | 372 | 0.770 |
Why?
| | Enoxaparin | 1 | 2023 | 68 | 0.760 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 332 | 0.730 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 337 | 0.720 |
Why?
| | Transplant Donor Site | 1 | 2021 | 3 | 0.720 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 25 | 0.710 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2016 | 670 | 0.680 |
Why?
| | Humans | 93 | 2025 | 141284 | 0.660 |
Why?
| | Pressure Ulcer | 2 | 2011 | 46 | 0.660 |
Why?
| | Craniosynostoses | 3 | 2025 | 56 | 0.640 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 65 | 0.590 |
Why?
| | Anticoagulants | 2 | 2023 | 724 | 0.580 |
Why?
| | Mastectomy | 7 | 2024 | 152 | 0.580 |
Why?
| | Kidney Transplantation | 5 | 2012 | 680 | 0.570 |
Why?
| | Tissue Transplantation | 3 | 2012 | 9 | 0.570 |
Why?
| | Nipples | 1 | 2018 | 12 | 0.560 |
Why?
| | Swine | 11 | 2024 | 821 | 0.550 |
Why?
| | Models, Animal | 4 | 2024 | 391 | 0.530 |
Why?
| | Female | 56 | 2025 | 75814 | 0.520 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2016 | 27 | 0.510 |
Why?
| | Tomography, X-Ray Computed | 3 | 2012 | 2765 | 0.490 |
Why?
| | Tissue and Organ Harvesting | 2 | 2014 | 74 | 0.490 |
Why?
| | Internet | 3 | 2025 | 683 | 0.470 |
Why?
| | Patient Safety | 1 | 2019 | 335 | 0.470 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 316 | 0.460 |
Why?
| | Frontal Bone | 2 | 2025 | 20 | 0.450 |
Why?
| | Treatment Outcome | 19 | 2025 | 11216 | 0.450 |
Why?
| | Malpractice | 2 | 2025 | 45 | 0.450 |
Why?
| | Groin | 1 | 2014 | 13 | 0.440 |
Why?
| | Perineum | 1 | 2014 | 38 | 0.430 |
Why?
| | Orbit | 2 | 2025 | 70 | 0.430 |
Why?
| | Middle Aged | 28 | 2025 | 34658 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1336 | 0.430 |
Why?
| | Cleft Lip | 2 | 2025 | 65 | 0.430 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 52 | 0.430 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 30 | 0.420 |
Why?
| | Bone Transplantation | 3 | 2025 | 90 | 0.420 |
Why?
| | Patient Satisfaction | 3 | 2024 | 695 | 0.420 |
Why?
| | Negative-Pressure Wound Therapy | 2 | 2024 | 29 | 0.420 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2025 | 99 | 0.420 |
Why?
| | Swine, Miniature | 8 | 2024 | 90 | 0.410 |
Why?
| | Interleukin-2 | 4 | 2024 | 448 | 0.410 |
Why?
| | Pelvis | 1 | 2014 | 117 | 0.400 |
Why?
| | Dogs | 5 | 2016 | 423 | 0.390 |
Why?
| | Facial Injuries | 2 | 2009 | 23 | 0.370 |
Why?
| | Face | 2 | 2013 | 174 | 0.370 |
Why?
| | Adult | 27 | 2025 | 39319 | 0.360 |
Why?
| | Prosthesis-Related Infections | 2 | 2024 | 98 | 0.350 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 45 | 0.350 |
Why?
| | Communications Media | 1 | 2011 | 4 | 0.350 |
Why?
| | United States | 19 | 2025 | 15298 | 0.340 |
Why?
| | Abdomen | 3 | 2024 | 138 | 0.340 |
Why?
| | Surgical Mesh | 2 | 2025 | 52 | 0.340 |
Why?
| | Bariatric Surgery | 2 | 2024 | 220 | 0.340 |
Why?
| | Attitude of Health Personnel | 2 | 2009 | 1178 | 0.330 |
Why?
| | Medicaid | 2 | 2025 | 450 | 0.330 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 122 | 0.330 |
Why?
| | Animals | 23 | 2025 | 37328 | 0.330 |
Why?
| | Computed Tomography Angiography | 2 | 2022 | 134 | 0.330 |
Why?
| | Length of Stay | 4 | 2025 | 1265 | 0.320 |
Why?
| | Obesity, Morbid | 2 | 2024 | 277 | 0.320 |
Why?
| | Coitus | 1 | 2010 | 23 | 0.320 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2010 | 39 | 0.320 |
Why?
| | Ultrasonography, Doppler | 1 | 2010 | 122 | 0.310 |
Why?
| | Osteomyelitis | 1 | 2011 | 143 | 0.310 |
Why?
| | Body Mass Index | 3 | 2024 | 2390 | 0.300 |
Why?
| | Arteries | 2 | 2013 | 260 | 0.300 |
Why?
| | Amputation, Traumatic | 1 | 2009 | 21 | 0.300 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5222 | 0.290 |
Why?
| | Hand Injuries | 1 | 2009 | 32 | 0.290 |
Why?
| | Traumatology | 1 | 2009 | 40 | 0.290 |
Why?
| | Suture Techniques | 2 | 2024 | 129 | 0.280 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 248 | 0.280 |
Why?
| | Vagina | 1 | 2010 | 188 | 0.270 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2008 | 21 | 0.270 |
Why?
| | Thigh | 1 | 2008 | 49 | 0.270 |
Why?
| | Skin Neoplasms | 3 | 2023 | 851 | 0.260 |
Why?
| | Hypertrophy | 2 | 2024 | 133 | 0.260 |
Why?
| | Reoperation | 5 | 2025 | 599 | 0.260 |
Why?
| | Sternum | 2 | 2024 | 29 | 0.260 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 101 | 0.260 |
Why?
| | Sternotomy | 2 | 2024 | 26 | 0.260 |
Why?
| | Back | 1 | 2006 | 11 | 0.250 |
Why?
| | Orthopedics | 1 | 2009 | 154 | 0.250 |
Why?
| | Wounds and Injuries | 2 | 2012 | 917 | 0.250 |
Why?
| | Cannabis | 2 | 2023 | 510 | 0.240 |
Why?
| | Internship and Residency | 3 | 2025 | 1230 | 0.240 |
Why?
| | Liability, Legal | 1 | 2025 | 42 | 0.230 |
Why?
| | Histocompatibility | 3 | 2014 | 21 | 0.230 |
Why?
| | Inflation, Economic | 1 | 2025 | 3 | 0.230 |
Why?
| | Facial Paralysis | 1 | 2025 | 24 | 0.230 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2025 | 66 | 0.220 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2025 | 30 | 0.220 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 25 | 0.220 |
Why?
| | CD47 Antigen | 1 | 2025 | 43 | 0.220 |
Why?
| | Transplantation Conditioning | 3 | 2016 | 184 | 0.220 |
Why?
| | Implant Capsular Contracture | 1 | 2024 | 5 | 0.220 |
Why?
| | Societies, Medical | 1 | 2009 | 859 | 0.220 |
Why?
| | Health Care Reform | 1 | 2025 | 109 | 0.220 |
Why?
| | Fibula | 1 | 2024 | 40 | 0.210 |
Why?
| | Gender Dysphoria | 1 | 2024 | 19 | 0.210 |
Why?
| | Anastomosis, Surgical | 3 | 2020 | 158 | 0.210 |
Why?
| | Physical Therapy Modalities | 2 | 2024 | 320 | 0.210 |
Why?
| | Cleft Palate | 1 | 2025 | 81 | 0.210 |
Why?
| | Publishing | 1 | 2025 | 109 | 0.210 |
Why?
| | Body Contouring | 1 | 2023 | 9 | 0.200 |
Why?
| | Malocclusion | 1 | 2023 | 24 | 0.200 |
Why?
| | Vitamin D Deficiency | 1 | 2025 | 188 | 0.200 |
Why?
| | Insurance | 1 | 2023 | 14 | 0.200 |
Why?
| | Fetus | 2 | 2005 | 797 | 0.200 |
Why?
| | Sezary Syndrome | 1 | 2023 | 45 | 0.200 |
Why?
| | Mandibular Fractures | 1 | 2023 | 17 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 62 | 0.200 |
Why?
| | Skull Fractures | 1 | 2023 | 38 | 0.200 |
Why?
| | Hindlimb | 2 | 2003 | 133 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2022 | 557 | 0.200 |
Why?
| | Seroma | 1 | 2022 | 3 | 0.190 |
Why?
| | Extremities | 2 | 2002 | 140 | 0.180 |
Why?
| | Weight Loss | 1 | 2008 | 794 | 0.180 |
Why?
| | Risk Factors | 7 | 2024 | 10490 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2162 | 0.180 |
Why?
| | Clinical Protocols | 1 | 2023 | 273 | 0.180 |
Why?
| | Incidental Findings | 1 | 2022 | 79 | 0.180 |
Why?
| | Educational Measurement | 1 | 2024 | 318 | 0.180 |
Why?
| | Quality of Life | 4 | 2025 | 3024 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3734 | 0.170 |
Why?
| | Hypotension | 1 | 2022 | 126 | 0.170 |
Why?
| | Transplantation, Autologous | 3 | 2024 | 282 | 0.170 |
Why?
| | Proteus vulgaris | 1 | 2000 | 1 | 0.170 |
Why?
| | Mediastinitis | 1 | 2000 | 3 | 0.170 |
Why?
| | Proteus Infections | 1 | 2000 | 5 | 0.170 |
Why?
| | Cyclosporine | 3 | 2016 | 265 | 0.170 |
Why?
| | Patient Education as Topic | 1 | 2025 | 771 | 0.170 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 174 | 0.160 |
Why?
| | Motivation | 1 | 2025 | 600 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 393 | 0.160 |
Why?
| | Time Factors | 6 | 2014 | 6951 | 0.160 |
Why?
| | Blood Vessel Prosthesis | 1 | 2000 | 139 | 0.150 |
Why?
| | Flow Cytometry | 4 | 2020 | 1182 | 0.150 |
Why?
| | Male | 19 | 2025 | 70140 | 0.150 |
Why?
| | Keloid | 1 | 2019 | 8 | 0.150 |
Why?
| | Dermis | 1 | 2019 | 33 | 0.150 |
Why?
| | Antigens | 2 | 2016 | 349 | 0.150 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2000 | 136 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 684 | 0.140 |
Why?
| | Postoperative Period | 2 | 2023 | 359 | 0.140 |
Why?
| | Mice, SCID | 3 | 2025 | 367 | 0.140 |
Why?
| | Incidence | 2 | 2023 | 2809 | 0.140 |
Why?
| | Tattooing | 1 | 2018 | 11 | 0.140 |
Why?
| | Fluorouracil | 1 | 2019 | 207 | 0.140 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 1117 | 0.140 |
Why?
| | Indocyanine Green | 2 | 2022 | 42 | 0.140 |
Why?
| | Chimera | 2 | 2011 | 60 | 0.130 |
Why?
| | Data Collection | 2 | 2011 | 655 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 81 | 0.130 |
Why?
| | Risk Assessment | 3 | 2024 | 3522 | 0.130 |
Why?
| | Graft vs Host Disease | 2 | 2016 | 256 | 0.130 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2016 | 89 | 0.120 |
Why?
| | Hernia, Ventral | 1 | 2016 | 24 | 0.120 |
Why?
| | Bupivacaine | 1 | 2016 | 38 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 565 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 118 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5948 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 76 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1133 | 0.110 |
Why?
| | Prospective Studies | 3 | 2021 | 7805 | 0.110 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1747 | 0.110 |
Why?
| | Leukocytes | 1 | 2016 | 293 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 568 | 0.110 |
Why?
| | Whole-Body Irradiation | 2 | 2012 | 77 | 0.110 |
Why?
| | Databases, Factual | 3 | 2025 | 1449 | 0.110 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 51 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 917 | 0.110 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Cadaver | 2 | 2010 | 305 | 0.110 |
Why?
| | Patient Selection | 2 | 2008 | 685 | 0.110 |
Why?
| | False Negative Reactions | 1 | 2014 | 60 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1505 | 0.110 |
Why?
| | CD3 Complex | 1 | 2014 | 106 | 0.110 |
Why?
| | Temporal Arteries | 1 | 2014 | 44 | 0.100 |
Why?
| | False Positive Reactions | 1 | 2014 | 122 | 0.100 |
Why?
| | Dissection | 1 | 2014 | 55 | 0.100 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 107 | 0.100 |
Why?
| | Endrin | 2 | 2023 | 13 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1866 | 0.100 |
Why?
| | Allografts | 1 | 2014 | 148 | 0.100 |
Why?
| | Random Allocation | 1 | 2014 | 369 | 0.100 |
Why?
| | Aged | 8 | 2025 | 24836 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 200 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 40 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3345 | 0.100 |
Why?
| | Prostheses and Implants | 1 | 2014 | 144 | 0.100 |
Why?
| | Health Care Costs | 1 | 2016 | 417 | 0.100 |
Why?
| | Pain Management | 1 | 2016 | 397 | 0.090 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 23 | 0.090 |
Why?
| | Recurrence | 2 | 2019 | 1108 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 287 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2014 | 497 | 0.090 |
Why?
| | Paternalism | 1 | 2011 | 4 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 893 | 0.090 |
Why?
| | Beneficence | 1 | 2011 | 20 | 0.090 |
Why?
| | Collagen | 1 | 2014 | 452 | 0.090 |
Why?
| | Marketing of Health Services | 1 | 2011 | 15 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2012 | 193 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 599 | 0.090 |
Why?
| | Personal Autonomy | 1 | 2011 | 54 | 0.090 |
Why?
| | Mice | 6 | 2025 | 17969 | 0.090 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1456 | 0.080 |
Why?
| | Intraoperative Care | 1 | 2011 | 63 | 0.080 |
Why?
| | Ethics, Medical | 1 | 2011 | 82 | 0.080 |
Why?
| | Professional Practice | 1 | 2011 | 62 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3502 | 0.080 |
Why?
| | Treatment Failure | 1 | 2012 | 355 | 0.080 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 179 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4414 | 0.080 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2010 | 37 | 0.080 |
Why?
| | Informed Consent | 1 | 2011 | 186 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2010 | 92 | 0.080 |
Why?
| | Radiography, Abdominal | 1 | 2010 | 44 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1973 | 0.080 |
Why?
| | Logistic Models | 2 | 2016 | 2098 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1546 | 0.080 |
Why?
| | North America | 1 | 2009 | 304 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2011 | 252 | 0.070 |
Why?
| | Child | 5 | 2025 | 22390 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 672 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 717 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2009 | 561 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 329 | 0.060 |
Why?
| | Back Injuries | 1 | 2006 | 6 | 0.060 |
Why?
| | Omentum | 1 | 2006 | 9 | 0.060 |
Why?
| | Wound Healing | 2 | 2023 | 349 | 0.060 |
Why?
| | Infant | 3 | 2025 | 9820 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2010 | 233 | 0.060 |
Why?
| | Linear Models | 1 | 2008 | 855 | 0.060 |
Why?
| | Case Management | 1 | 2006 | 65 | 0.060 |
Why?
| | Cytokines | 1 | 2014 | 2079 | 0.060 |
Why?
| | Debridement | 1 | 2006 | 88 | 0.060 |
Why?
| | Insurance, Liability | 1 | 2025 | 9 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1312 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1075 | 0.060 |
Why?
| | Current Procedural Terminology | 1 | 2025 | 20 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2005 | 229 | 0.060 |
Why?
| | Craniotomy | 1 | 2025 | 78 | 0.060 |
Why?
| | Silicone Gels | 1 | 2024 | 4 | 0.060 |
Why?
| | Operative Time | 1 | 2025 | 158 | 0.060 |
Why?
| | Melanoma | 1 | 2012 | 786 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2069 | 0.050 |
Why?
| | Licensure, Medical | 1 | 2024 | 19 | 0.050 |
Why?
| | School Admission Criteria | 1 | 2024 | 32 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2024 | 84 | 0.050 |
Why?
| | Burns | 1 | 2009 | 350 | 0.050 |
Why?
| | Esthetics | 1 | 2024 | 47 | 0.050 |
Why?
| | Pectoralis Muscles | 1 | 2024 | 20 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1059 | 0.050 |
Why?
| | Comprehension | 1 | 2025 | 182 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2025 | 147 | 0.050 |
Why?
| | Hydrocodone | 1 | 2023 | 19 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 86 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 536 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2025 | 6270 | 0.050 |
Why?
| | Tobacco Use | 1 | 2023 | 65 | 0.050 |
Why?
| | Adolescent | 4 | 2025 | 22116 | 0.050 |
Why?
| | Mandible | 1 | 2023 | 69 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4180 | 0.050 |
Why?
| | Chemoprevention | 1 | 2023 | 95 | 0.050 |
Why?
| | Young Adult | 4 | 2024 | 13727 | 0.050 |
Why?
| | Electromyography | 1 | 2025 | 411 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 406 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 239 | 0.050 |
Why?
| | Physicians | 1 | 2011 | 930 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5653 | 0.050 |
Why?
| | Umbilicus | 1 | 2022 | 19 | 0.050 |
Why?
| | Genetic Testing | 1 | 2025 | 462 | 0.050 |
Why?
| | Transplantation Immunology | 1 | 2002 | 31 | 0.050 |
Why?
| | Vitamin D | 1 | 2025 | 401 | 0.050 |
Why?
| | Perfusion | 1 | 2022 | 226 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2002 | 72 | 0.040 |
Why?
| | Pregnancy | 1 | 2014 | 7035 | 0.040 |
Why?
| | Cicatrix | 1 | 2022 | 70 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 571 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 69 | 0.040 |
Why?
| | Insurance, Health | 1 | 2023 | 296 | 0.040 |
Why?
| | Povidone-Iodine | 1 | 2000 | 11 | 0.040 |
Why?
| | Musculoskeletal System | 1 | 2001 | 49 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2001 | 136 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 70 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 91 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 80 | 0.040 |
Why?
| | Child, Preschool | 2 | 2025 | 11511 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 425 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2000 | 121 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 370 | 0.040 |
Why?
| | Patient Readmission | 1 | 2025 | 698 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 529 | 0.040 |
Why?
| | Forelimb | 1 | 1999 | 39 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 612 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 304 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 2019 | 35 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2001 | 266 | 0.040 |
Why?
| | Lymphocytes | 1 | 2001 | 390 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2019 | 115 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 802 | 0.040 |
Why?
| | Veterans | 1 | 2010 | 1519 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 711 | 0.040 |
Why?
| | Tacrolimus | 1 | 1999 | 199 | 0.030 |
Why?
| | Skin | 1 | 2003 | 760 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 48 | 0.030 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 54 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1362 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2019 | 332 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 874 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 3007 | 0.030 |
Why?
| | Narcotics | 1 | 2016 | 54 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 86 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 436 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2016 | 101 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1073 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5556 | 0.030 |
Why?
| | Nerve Block | 1 | 2016 | 97 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 538 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 304 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 918 | 0.030 |
Why?
| | Tissue Expansion Devices | 1 | 2014 | 5 | 0.030 |
Why?
| | Tissue Expansion | 1 | 2014 | 10 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 669 | 0.030 |
Why?
| | Cellulitis | 1 | 2014 | 55 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2014 | 130 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5809 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 612 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2017 | 560 | 0.020 |
Why?
| | Leukocyte Transfusion | 1 | 2012 | 4 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1761 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 207 | 0.020 |
Why?
| | Fluorescence | 1 | 2011 | 161 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1706 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2529 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7948 | 0.020 |
Why?
| | Burns, Electric | 1 | 2009 | 26 | 0.020 |
Why?
| | Equipment Design | 1 | 2011 | 528 | 0.020 |
Why?
| | Neurofibromatosis 1 | 1 | 2009 | 55 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1671 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 1037 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4599 | 0.020 |
Why?
| | Smoking | 1 | 2014 | 1576 | 0.020 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 250 | 0.010 |
Why?
| | Recovery of Function | 1 | 2009 | 684 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1078 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 244 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2001 | 152 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4149 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1996 | 0.010 |
Why?
|
|
Mathes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|